The Experts below are selected from a list of 4374 Experts worldwide ranked by ideXlab platform
Susan M Domchek - One of the best experts on this subject based on the ideXlab platform.
-
uptake of brca 1 2 and Oncotype DX testing by medical and surgical oncologists
Breast Cancer Research and Treatment, 2018Co-Authors: Yonina R Murcianogoroff, Susan M Domchek, Anne Marie Mccarthy, Mirar Bristol, Peter W Groeneveld, Nkiru U Motanya, Katrina ArmstrongAbstract:Purpose The diffusion of genomic testing is critical to the success of precision medicine, but there is limited information on oncologists’ uptake of genetic technology. We aimed to assess the frequency with which medical oncologists and surgeons order BRCA 1/2 and Oncotype DX testing for breast cancer patients.
-
Uptake of BRCA 1 / 2 and Oncotype DX testing by medical and surgical oncologists
Breast Cancer Research and Treatment, 2018Co-Authors: Yonina R. Murciano-goroff, Susan M Domchek, Anne Marie Mccarthy, Mirar Bristol, Peter W Groeneveld, U. Nkiru Motanya, Katrina ArmstrongAbstract:Purpose The diffusion of genomic testing is critical to the success of precision medicine, but there is limited information on oncologists’ uptake of genetic technology. We aimed to assess the frequency with which medical oncologists and surgeons order BRCA 1/2 and Oncotype DX testing for breast cancer patients.
-
Oncotype DX scores in brca1 and brca2 associated breast cancer
Journal of Clinical Oncology, 2015Co-Authors: Nicholas Patrick Mcandrew, Kara N Maxwell, Jill Stopfer, Jacquelyn Powers, Amanda Brandt, Jessica M Long, Katherine L Nathanson, Susan M DomchekAbstract:541 Background: The Oncotype DX score is widely used to evaluate recurrence risk and potential benefit of chemotherapy in stage 1, estrogen receptor (ER) positive, Her2 negative tumors. Oncotype DX was developed and validated in sporadic breast cancer patients. No data are available regarding Oncotype DX results in BRCA1/2 mutation carriers. The purpose of this study is to determine the distribution of Oncotype DX scores in patients with BRCA1/2 associated cancers, as well as subsequent therapy and disease course for this population. Methods: 18 patients were identified between 2006-2013 who had deleterious BRCA1/2 mutations and stage 1, ER positive, Her2 negative, node negative invasive breast cancer. Data regarding Oncotype DX scores, subsequent therapy (including local, prophylactic, hormonal, and chemotherapy), and length of follow-up was collected. Results: The distribution of Oncotype DX scores was similar in this population as compared to prior published data on patients with sporadic tumors, with ...
-
Utilization of Oncotype DX in node-negative, ER-positive breast cancer patients
Journal of Clinical Oncology, 2007Co-Authors: H. Patel, K. Hook, C. Kaplan, Rosemarie Davidson, Angela Demichele, Susan M DomchekAbstract:11067 Background: The 21 gene RT-PCR assay Oncotype DX (Genomic Health, CA) stratifies patients into low, intermediate and high risk for systemic recurrence. The objective of this study was to examine the patterns of use of Oncotype DX in a single institution. Methods: All patients who had ODX testing requested by the University of Pennsylvania were identified and recurrence scores (RS) obtained. Patient and tumor characteristics, as well as treatment administered, were obtained by chart review for analysis. Results: 100 ODX tests were ordered between 1/1/05–11/30/06. RS results classified 51% of breast cancers as low risk, 38% intermediate risk, and 11% high risk. Characteristics of the tumors of the overall population and by RS group are shown in Table. 99% of patients received hormonal therapy. Of the low risk patients, only one patient was treated with chemotherapy (2%) while 34% of the intermediate risk group and 80% of the high risk group received chemotherapy. Notably, only 4/100 patients with ODX ...
Rohit Bhargava - One of the best experts on this subject based on the ideXlab platform.
-
Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis
Modern Pathology, 2013Co-Authors: Molly Klein, David J Dabbs, Adam Brufsky, Yongli Shuai, Rachel C Jankowitz, Shannon Puhalla, Rohit BhargavaAbstract:Oncotype DX is a commercial assay frequently used for making chemotherapy decisions in estrogen receptor (ER)-positive breast cancers. The result is reported as a recurrence score ranging from 0 to 100, divided into low-risk (
-
prediction of the Oncotype DX recurrence score use of pathology generated equations derived by linear regression analysis
Modern Pathology, 2013Co-Authors: Molly Klein, David J Dabbs, Adam Brufsky, Yongli Shuai, Rachel C Jankowitz, Shannon Puhalla, Rohit BhargavaAbstract:Oncotype DX is a commercial assay frequently used for making chemotherapy decisions in estrogen receptor (ER)-positive breast cancers. The result is reported as a recurrence score ranging from 0 to 100, divided into low-risk (<18), intermediate-risk (18–30), and high-risk (≥31) categories. Our pilot study showed that recurrence score can be predicted by an equation incorporating standard morphoimmunohistologic variables (referred to as original Magee equation). Using a data set of 817 cases, we formulated three additional equations (referred to as new Magee equations 1, 2, and 3) to predict the recurrence score category for an independent set of 255 cases. The concordance between the risk category of Oncotype DX and our equations was 54.3%, 55.8%, 59.4%, and 54.4% for original Magee equation, new Magee equations 1, 2, and 3, respectively. When the intermediate category was eliminated, the concordance increased to 96.9%, 100%, 98.6%, and 98.7% for original Magee equation, new Magee equations 1, 2, and 3, respectively. Even when the estimated recurrence score fell in the intermediate category with any of the equations, the actual recurrence score was either intermediate or low in more than 80% of the cases. Any of the four equations can be used to estimate the recurrence score depending on available data. If the estimated recurrence score is clearly high or low, the oncologists should not expect a dramatically different result from Oncotype DX, and the Oncotype DX test may not be needed. Conversely, an Oncotype DX result that is dramatically different from what is expected based on standard morphoimmunohistologic variables should be thoroughly investigated.
-
histopathologic variables predict Oncotype DX recurrence score
Modern Pathology, 2008Co-Authors: Melina B Flanagan, David J Dabbs, Adam Brufsky, Sushil Beriwal, Rohit BhargavaAbstract:Oncotype DX™ is a commercially available reverse transcriptase-polymerase chain reaction based assay that provides a Recurrence Score (RS) and has been shown to provide prognostic and predictive information in estrogen receptor-positive lymph node-negative breast cancers. Independent studies of its utility in routine practice are lacking. Slides and surgical pathology reports from 42 cases of breast carcinomas evaluated by Oncotype DX™ were retrospectively reviewed to determine patient age, tumor size, histologic grade, estrogen and progesterone receptor (ER and PR) and ERBB2 (HER-2/neu) data, with ER and PR reported as a semi-quantitative score reflecting both intensity of staining and proportion of positive cells. We show here that Recurrence Score is significantly correlated with tubule formation, nuclear grade, mitotic count, ER immunohistochemical score, PR immunohistochemical score, and HER-2/neu status, and that the equation RS=13.424+5.420 (nuclear grade) +5.538 (mitotic count) −0.045 (ER immunohistochemical score) −0.030 (PR immunohistochemical score) +9.486 (HER-2/neu) predicts the Recurrence Score with an R2 of 0.66, indicating that the full model accounts for 66% of the data variability. Although the Oncotype DX™ Recurrence Score holds potential, further validation of its independent value beyond that of histopathologic analysis is necessary before it can be implemented in clinical decision making.
Susan Fineberg - One of the best experts on this subject based on the ideXlab platform.
-
The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX® Recurrence Score in ER-Positive Invasive Breast Cancers
Frontiers in Pharmacology, 2019Co-Authors: Pascale A. Cohen, Olivier Loudig, Joseph Albanese, Susan FinebergAbstract:We assessed mRNA and protein expression levels of the ZN217 oncogene in 17 clinical FFPE ER-positive invasive breast cancer specimens with known (low or high) Oncotype DX® Recurrence Scores. This study shows that mRNA or nuclear protein levels of the ZNF217 significantly correlate with Oncotype DX® Recurrence Score.
-
correlation of histopathologic features of ductal carcinoma in situ of the breast with the Oncotype DX dcis score
Modern Pathology, 2015Co-Authors: Adriana Knopfelmacher, Yungtai Lo, Nella Shapiro, Susan FinebergAbstract:The Oncotype DX Breast Cancer Assay for ductal carcinoma in situ is used to determine local recurrence risk in patients with ductal carcinoma in situ. The results help select patients with low-risk ductal carcinoma in situ who could forgo radiation therapy after conservative surgery. The genes assessed include five proliferation genes, progesterone receptor (PR), and GSTM-1. Our objective was to determine if PR, mitotic counting, or any other pathologic feature of ductal carcinoma in situ could predict the Oncotype DX DCIS Score. We identified 46 cases of ductal carcinoma in situ with a Oncotype DX DCIS Score. In addition to information obtained from routine pathology, we counted mitotic figures in the ductal carcinoma in situ and noted presence of dense chronic inflammatory infiltrate surrounding ductal carcinoma in situ. We found that PR ≥90% (P=0.004), mitotic count ≤1 (P=0.045), estrogen receptor ≥90% (P=0.046), and low nuclear grade (P 1 mitotic figure, and/or presence of dense chronic inflammation around ductal carcinoma in situ (100% specificity). Our study suggests using a combination of PR (≥90% vs negative) with mitotic count in ductal carcinoma in situ (≤1 vs >1) and dense chronic inflammation around ductal carcinoma in situ one could predict the Oncotype DX DCIS score. Mitotic counting and evaluation of immune response might provide prognostic information in ductal carcinoma in situ.
-
utilization of Oncotype DX in an inner city population race or place
International journal of breast cancer, 2013Co-Authors: Amber A. Guth, Rebeca Franco, Susan Fineberg, Nina A. BickellAbstract:Oncotype DX, a 21-gene-array analysis, can guide chemotherapy treatment decisions for women with ER+ tumors. Of 225 ER+ women participating in a patient assistance trial, 23% underwent Oncotype DX testing: 31% of whites, 21% of blacks, and 14% of Hispanics (P = 0.04) were tested. Only 3 white women were treated at municipal hospitals and none was tested. 3% of women treated in municipal hospital as compared to 30% treated at tertiary referral centers were tested (P = 0.001). Within tertiary referral centers, there was no racial difference in testing: 32% of whites, 29% of blacks, and 19% of Hispanics (P = 0.25). Multivariate analysis (model c-statistic = 0.76; P < 0.0001) revealed that women who underwent testing were more likely to have stage 1B (RR = 1.70; 95% CI: 1.45–1.85) and to be treated after 2007 (RR = 1.34; 95% CI: 1.01–1.65) and less likely to be treated at a municipal hospital (RR = 0.20; 95% CI: 0.04–0.94). Women treated at municipal hospitals were less likely to undergo testing resulting in a misleading racial disparity that is driven by site of care. As Oncotype DX can reduce overuse of chemotherapy, it is imperative to expand testing to those who could benefit from yet experience underuse of this test, namely, women treated at safety net hospitals. This trial is registered with NCT00233077.
Debra A Patt - One of the best experts on this subject based on the ideXlab platform.
-
evaluating use characteristics for the Oncotype DX 21 gene recurrence score and concordance with chemotherapy use in early stage breast cancer
Journal of Oncology Practice, 2013Co-Authors: Clara Chen, Rahul Dhanda, Wanyu Tseng, Michael Forsyth, Debra A PattAbstract:Purpose: Oncotype DX 21-gene assay recurrence score (RS) predicts recurrence of early-stage breast cancer (ESBC). We investigated whether patient, tumor, or practice characteristics drive its use and explored Oncotype DX RS and chemotherapy use in subgroups. Methods: Patients with ESBC with documented estrogen receptor–positive, lymph node–negative, human epidermal growth factor receptor 2–negative tumors registered within McKesson Specialty Health’s iKnowMed electronic health record were included. Patient and practice characteristics by region and size were analyzed. The association between Oncotype DX RS value and use of chemotherapy were assessed. Results: The study included 6,229 patients. Of these, 1,822 (29%) had an Oncotype DX RS result. Test use was 36%, 38%, 34%, 25%, and 6%, respectively, in patients age 45, 46-55, 56-65, 66-75, and 76 years; 33%, 25%, and 9% in patients with Eastern Cooperative Oncology Group performance status of 0, 1, and 2; 7%, 9%, 25%, 38%, 27%, and 10% in T1mic, T1a, T1b, T1c, T2, and T3 tumors; and 26%, 32%, and 33% for grades 1, 2 ,and 3 tumors. Of the 1,822 patients with available Oncotype DX RS, adjuvant chemotherapy use was 6%, 42%, and 84% in the low-, intermediate-, and high-risk groups. Conclusion: Patients who were younger, had better ECOG performance status, or had higher grade tumors were more likely to undergo RS testing. It appears that the RS test may have influenced the decision about whether to administer adjuvant chemotherapy: a low RS score was associated with lower chemotherapy use and a high RS score was associated with higher chemotherapy use.
Evelyn P Whitlock - One of the best experts on this subject based on the ideXlab platform.
-
Oncotype DX tumor gene expression profiling in stage ii colon cancer application prognostic risk prediction
PLOS Currents, 2010Co-Authors: Elizabeth M Webber, Evelyn P WhitlockAbstract:Overall five-year survival for patients with stage-II colon cancer averages 75% after surgery alone. However, some of these patients have poorer outcomes, similar to patients with stage-III disease. The proposed use of the Oncotype DX assay is to improve risk stratification for recurrence in stage-II colon cancer. Abstract Overall five-year survival for patients with stage-II colon cancer averages 75% after surgery alone. However, some of these patients have poorer outcomes, similar to patients with stage-III disease. The proposed use of the Oncotype DX assay is to improve risk stratification for recurrence in stage-II colon cancer. Abstract Overall five-year survival for patients with stage-II colon cancer averages 75% after surgery alone. However, some of these patients have poorer outcomes, similar to patients with stage-III disease. The proposed use of the Oncotype DX assay is to improve risk stratification for recurrence in stage-II colon cancer.
